Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 378

1.

[Orphan drugs from the perspective of the Drug Commission of the German Medical Association : Opportunities and challenges].

Ludwig WD.

Internist (Berl). 2019 Apr;60(4):399-404. doi: 10.1007/s00108-019-0578-7. Review. German. No abstract available.

PMID:
30859278
2.

Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.

Braess J, Amler S, Kreuzer KA, Spiekermann K, Lindemann HW, Lengfelder E, Graeven U, Staib P, Ludwig WD, Biersack H, Ko YD, Uppenkamp MJ, De Wit M, Korsten S, Peceny R, Gaska T, Schiel X, Behringer DM, Kiehl MG, Zinngrebe B, Meckenstock G, Roemer E, Medgenberg D, Spaeth-Schwalbe E, Massenkeil G, Hindahl H, Schwerdtfeger R, Trenn G, Sauerland C, Koch R, Lablans M, Faldum A, Görlich D, Bohlander SK, Schneider S, Dufour A, Buske C, Fiegl M, Subklewe M, Braess B, Unterhalt M, Baumgartner A, Wörmann B, Beelen D, Hiddemann W; AML-CG.

Leukemia. 2018 Dec;32(12):2558-2571. doi: 10.1038/s41375-018-0268-9. Epub 2018 Oct 1.

3.

Expression of CD56 defines a distinct subgroup in childhood T-ALL with inferior outcome. Results of the ALL-BFM 2000 trial.

Fuhrmann S, Schabath R, Möricke A, Zimmermann M, Kunz JB, Kulozik AE, Ludwig WD, Schrappe M, Karawajew L, Ratei R.

Br J Haematol. 2018 Oct;183(1):96-103. doi: 10.1111/bjh.15503. Epub 2018 Jul 20.

PMID:
30028023
4.

IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.

Stanulla M, Dagdan E, Zaliova M, Möricke A, Palmi C, Cazzaniga G, Eckert C, Te Kronnie G, Bourquin JP, Bornhauser B, Koehler R, Bartram CR, Ludwig WD, Bleckmann K, Groeneveld-Krentz S, Schewe D, Junk SV, Hinze L, Klein N, Kratz CP, Biondi A, Borkhardt A, Kulozik A, Muckenthaler MU, Basso G, Valsecchi MG, Izraeli S, Petersen BS, Franke A, Dörge P, Steinemann D, Haas OA, Panzer-Grümayer R, Cavé H, Houlston RS, Cario G, Schrappe M, Zimmermann M; TRANSCALL Consortium; International BFM Study Group.

J Clin Oncol. 2018 Apr 20;36(12):1240-1249. doi: 10.1200/JCO.2017.74.3617. Epub 2018 Mar 2.

PMID:
29498923
5.

A Patient with Non-Hodgkin Lymphoma and Nonspecific Interstitial Pneumonia during Ibrutinib Therapy.

Jungmann S, Ludwig WD, Schönfeld N, Blum TG, Großwendt C, Boch C, Rehbock B, Griff S, Schmittel A, Bauer TT.

Case Rep Oncol Med. 2017;2017:5640186. doi: 10.1155/2017/5640186. Epub 2017 Nov 10.

6.

Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).

Schrappe M, Bleckmann K, Zimmermann M, Biondi A, Möricke A, Locatelli F, Cario G, Rizzari C, Attarbaschi A, Valsecchi MG, Bartram CR, Barisone E, Niggli F, Niemeyer C, Testi AM, Mann G, Ziino O, Schäfer B, Panzer-Grümayer R, Beier R, Parasole R, Göhring G, Ludwig WD, Casale F, Schlegel PG, Basso G, Conter V.

J Clin Oncol. 2018 Jan 20;36(3):244-253. doi: 10.1200/JCO.2017.74.4946. Epub 2017 Nov 17.

7.

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.

Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A.

Lancet. 2018 Dec 23;390(10114):2790-2802. doi: 10.1016/S0140-6736(17)32134-7. Epub 2017 Oct 20.

PMID:
29061295
8.

NOTCH1 mutation, TP53 alteration and myeloid antigen expression predict outcome heterogeneity in children with first relapse of T-cell acute lymphoblastic leukemia.

Hof J, Kox C, Groeneveld-Krentz S, Bandapalli OR, Karawajew L, Schedel K, Kunz JB, Eckert C, Ludwig WD, Ratei R, Rhein P, Henze G, Muckenthaler MU, Kulozik AE, von Stackelberg A, Kirschner-Schwabe R.

Haematologica. 2017 Jul;102(7):e249-e252. doi: 10.3324/haematol.2016.157792. Epub 2017 Mar 30. No abstract available.

9.

Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials.

Bröckelmann PJ, Goergen H, Kohnhorst C, von Tresckow B, Moccia A, Markova J, Meissner J, Kerkhoff A, Ludwig WD, Fuchs M, Borchmann P, Engert A.

J Clin Oncol. 2017 May 1;35(13):1444-1450. doi: 10.1200/JCO.2016.71.3289. Epub 2017 Feb 27.

PMID:
28240973
10.

AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia.

Dworzak MN, Buldini B, Gaipa G, Ratei R, Hrusak O, Luria D, Rosenthal E, Bourquin JP, Sartor M, Schumich A, Karawajew L, Mejstrikova E, Maglia O, Mann G, Ludwig WD, Biondi A, Schrappe M, Basso G; International-BFM-FLOW-network.

Cytometry B Clin Cytom. 2018 Jan;94(1):82-93. doi: 10.1002/cyto.b.21518. Epub 2017 Feb 21.

11.

Drug information by public health and regulatory institutions: Results of an 8-country survey in Europe.

Formoso G, Font-Pous M, Ludwig WD, Phizackerley D, Bijl D, Erviti J, Pospíšilová B, Montastruc JL.

Health Policy. 2017 Mar;121(3):257-264. doi: 10.1016/j.healthpol.2016.12.007. Epub 2016 Dec 29.

PMID:
28073580
12.

[Flow-cytometric immunophenotyping in clinical diagnostics].

Ostendorf BN, Hansmann L, Ludwig WD, Dörken B, Ratei R, Westermann J.

Dtsch Med Wochenschr. 2016 Oct;141(21):1569-1574. Epub 2016 Oct 17. Review. German.

PMID:
27750345
13.

[Biosimilars in oncology: a therapeutic alternative to the reference products?]

Ludwig WD, Dicheva S.

Z Gastroenterol. 2016 Nov;54(11):1223-1229. Epub 2016 Oct 10. Review. German.

PMID:
27723912
14.

Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia.

Krug U, Berdel WE, Gale RP, Haferlach C, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Staib P, Beelen D, Serve H, Schliemann C, Stelljes M, Balleisen L, Maschmeyer G, Grüneisen A, Eimermacher H, Giagounidis A, Rasche H, Hehlmann R, Lengfelder E, Thiel E, Reichle A, Aul C, Ludwig WD, Kern W, Haferlach T, Köpcke W, Görlich D, Sauerland MC, Heinecke A, Wörmann BJ, Hiddemann W, Büchner T.

Leukemia. 2016 Jun;30(6):1230-6. doi: 10.1038/leu.2016.25. Epub 2016 Feb 9.

PMID:
26859081
15.

Declaration and Handling of Conflicts of Interest in Guidelines: A Study of S1 Guidelines From German Specialist Societies From 2010-2013.

Schott G, Lieb K, König J, Mühlbauer B, Niebling W, Pachl H, Schmutz S, Ludwig WD.

Dtsch Arztebl Int. 2015 Jun 26;112(26):445-51. doi: 10.3238/arztebl.2015.0445.

16.

Metamizole (dipyrone)-associated agranulocytosis. An analysis of German spontaneous reports 1990-2012.

Stammschulte T, Ludwig WD, Mühlbauer B, Bronder E, Gundert-Remy U.

Eur J Clin Pharmacol. 2015 Sep;71(9):1129-38. doi: 10.1007/s00228-015-1895-y. Epub 2015 Jul 15.

PMID:
26169297
17.

Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.

Karawajew L, Dworzak M, Ratei R, Rhein P, Gaipa G, Buldini B, Basso G, Hrusak O, Ludwig WD, Henze G, Seeger K, von Stackelberg A, Mejstrikova E, Eckert C.

Haematologica. 2015 Jul;100(7):935-44. doi: 10.3324/haematol.2014.116707. Epub 2015 May 22.

18.

Submicroscopic genomic rearrangements change gene expression in T-cell large granular lymphocyte leukemia.

Iżykowska K, Zawada M, Nowicka K, Grabarczyk P, Kuss AW, Weissmann R, Busemann C, Ludwig WD, Schmidt CA, Przybylski GK.

Eur J Haematol. 2014 Aug;93(2):143-9. doi: 10.1111/ejh.12318. Epub 2014 Apr 9.

PMID:
24649974
19.

In reply.

Schott G, Pachl H, Ludwig WD, Dünnweber C, Mühlbauer B, Niebling W.

Dtsch Arztebl Int. 2014 Jan 17;111(3):37-8. doi: 10.3238/arztebl.2014.0037b. No abstract available.

20.

Molecular characterization and clinical course of MLL-ACTN4 rearrangement in therapy-related hematologic malignancies.

Yang JJ, Park TS, Lee ST, Seo JY, Oh SH, Cho EH, Burmeister T, Ludwig WD, Meyer C, Marschalek R, Kim HJ, Kim SH.

Haematologica. 2014 Apr;99(4):e49-51. doi: 10.3324/haematol.2013.102798. Epub 2014 Feb 21. No abstract available.

21.

Does the pharmaceutical industry influence guidelines?: two examples from Germany.

Schott G, Dünnweber C, Mühlbauer B, Niebling W, Pachl H, Ludwig WD.

Dtsch Arztebl Int. 2013 Sep;110(35-36):575-83. doi: 10.3238/arztebl.2013.0575. Epub 2013 Sep 2.

22.

High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.

Cario G, Rhein P, Mitlöhner R, Zimmermann M, Bandapalli OR, Romey R, Moericke A, Ludwig WD, Ratei R, Muckenthaler MU, Kulozik AE, Schrappe M, Stanulla M, Karawajew L.

Haematologica. 2014 Jan;99(1):103-10. doi: 10.3324/haematol.2013.090225. Epub 2013 Aug 2.

23.

Peripheral blood sCD3⁻ CD4⁺ T cells: a useful diagnostic tool in angioimmunoblastic T cell lymphoma.

Singh A, Schabath R, Ratei R, Stroux A, Klemke CD, Nebe T, Flörcken A, van Lessen A, Anagnostopoulos I, Dörken B, Ludwig WD, Pezzutto A, Westermann J.

Hematol Oncol. 2014 Mar;32(1):16-21. doi: 10.1002/hon.2080. Epub 2013 Jun 24.

PMID:
23798351
24.

Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.

Ratei R, Schabath R, Karawajew L, Zimmermann M, Möricke A, Schrappe M, Ludwig WD.

Klin Padiatr. 2013 May;225 Suppl 1:S34-9. doi: 10.1055/s-0033-1337961. Epub 2013 May 22.

PMID:
23700065
25.

Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000.

Schrappe M, Möricke A, Reiter A, Henze G, Welte K, Gadner H, Ludwig WD, Ritter J, Harbott J, Mann G, Klingebiel T, Gruhn B, Niemeyer C, Kremens B, Niggli F, Debatin KM, Ratei R, Stanulla M, Beier R, Cario G, Schrauder A, Zimmermann M.

Klin Padiatr. 2013 May;225 Suppl 1:S62-72. doi: 10.1055/s-0033-1337966. Epub 2013 May 22.

PMID:
23700060
27.

[Aspects of acute palliative medical care in need of improvement].

Gockel M, Ludwig WD.

HNO. 2013 Mar;61(3):224-5. doi: 10.1007/s00106-012-2658-z. German. No abstract available.

PMID:
23467890
28.

NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia.

Bandapalli OR, Zimmermann M, Kox C, Stanulla M, Schrappe M, Ludwig WD, Koehler R, Muckenthaler MU, Kulozik AE.

Haematologica. 2013 Jun;98(6):928-36. doi: 10.3324/haematol.2012.073585. Epub 2013 Jan 24.

29.

Acquired deficiency of coagulation factor XIII--possible evidence for a new link between coagulation and infection from a case.

Lodemann P, Kolbeck H, Held TK, Ivaskevicius V, Oldenburg J, Schweigerer L, Ludwig WD, Peetz D.

Ann Hematol. 2013 Mar;92(3):427-9. doi: 10.1007/s00277-012-1582-3. Epub 2012 Sep 28. No abstract available.

PMID:
23053180
30.

IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.

Dörge P, Meissner B, Zimmermann M, Möricke A, Schrauder A, Bouquin JP, Schewe D, Harbott J, Teigler-Schlegel A, Ratei R, Ludwig WD, Koehler R, Bartram CR, Schrappe M, Stanulla M, Cario G.

Haematologica. 2013 Mar;98(3):428-32. doi: 10.3324/haematol.2011.056135. Epub 2012 Aug 8.

31.

Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies.

Mentzer D, Prestel J, Adams O, Gold R, Hartung HP, Hengel H, Kieseier BC, Ludwig WD, Keller-Stanislawski B.

J Neurol Neurosurg Psychiatry. 2012 Sep;83(9):927-33. doi: 10.1136/jnnp-2012-302478. Epub 2012 Jul 17.

PMID:
22807558
32.

Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia.

Gaipa G, Cazzaniga G, Valsecchi MG, Panzer-Grümayer R, Buldini B, Silvestri D, Karawajew L, Maglia O, Ratei R, Benetello A, Sala S, Schumich A, Schrauder A, Villa T, Veltroni M, Ludwig WD, Conter V, Schrappe M, Biondi A, Dworzak MN, Basso G.

Haematologica. 2012 Oct;97(10):1582-93. doi: 10.3324/haematol.2011.060426. Epub 2012 May 11.

33.

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies.

Gökbuget N, Kneba M, Raff T, Trautmann H, Bartram CR, Arnold R, Fietkau R, Freund M, Ganser A, Ludwig WD, Maschmeyer G, Rieder H, Schwartz S, Serve H, Thiel E, Brüggemann M, Hoelzer D; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia.

Blood. 2012 Aug 30;120(9):1868-76. Epub 2012 Mar 22.

PMID:
22442346
34.

Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study.

Feldt S, Schüssel K, Quinzler R, Franzmann A, Czeche S, Ludwig WD, Schulz M.

Eur J Cancer. 2012 May;48(7):974-81. doi: 10.1016/j.ejca.2012.01.036. Epub 2012 Feb 28.

PMID:
22382202
35.

[Off-label therapy: current problems from the perspective of the Pharmaceutical Commission of the German Medical Profession].

Janzen RW, Ludwig WD; Arzneimittelkommission der deutschen Ärzteschaft, Berlin.

Z Rheumatol. 2012 Feb;71(2):108-10, 112-8. doi: 10.1007/s00393-011-0901-8. Review. German.

PMID:
22370801
36.

[Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].

Ludwig WD.

Z Evid Fortbild Qual Gesundhwes. 2012;106(1):11-22. doi: 10.1016/j.zefq.2011.12.001. Epub 2012 Jan 10. Review. German.

PMID:
22325103
37.

[Clinical trials in oncology: deficits and proposals for solution].

Schott G, Gökbuget N, Pachl H, Ludwig WD.

Z Evid Fortbild Qual Gesundhwes. 2011;105(9):657-64. doi: 10.1016/j.zefq.2011.01.006. Epub 2011 Feb 12. German.

PMID:
22152423
38.

CALM/AF10-positive leukemias show upregulation of genes involved in chromatin assembly and DNA repair processes and of genes adjacent to the breakpoint at 10p12.

Mulaw MA, Krause A, Deshpande AJ, Krause LF, Rouhi A, La Starza R, Borkhardt A, Buske C, Mecucci C, Ludwig WD, Lottaz C, Bohlander SK.

Leukemia. 2012 May;26(5):1012-9. doi: 10.1038/leu.2011.307. Epub 2011 Nov 8. Erratum in: Leukemia. 2012 Dec;26(12):2570. Krause, A J [corrected to Krause, A].

PMID:
22064352
39.

Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome.

Zeidler L, Zimmermann M, Möricke A, Meissner B, Bartels D, Tschan C, Schrauder A, Cario G, Goudeva L, Jäger S, Ratei R, Ludwig WD, Teigler-Schlegel A, Skokowa J, Koehler R, Bartram CR, Riehm H, Schrappe M, Welte K, Stanulla M.

Haematologica. 2012 Mar;97(3):402-9. doi: 10.3324/haematol.2011.045229. Epub 2011 Nov 4.

40.

Apheresis-related enrichment of CD26++ T lymphocytes: phenotypic characterization and correlation with unfavorable outcome in autologous hematopoietic progenitor cell transplantation.

Hildebrandt M, Dijkstra D, Gollasch H, Daemen K, Stevanovic-Meyer M, Ludwig WD.

Transfusion. 2012 Apr;52(4):765-76. doi: 10.1111/j.1537-2995.2011.03351.x. Epub 2011 Sep 26.

PMID:
21950525
41.

Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.

Hof J, Krentz S, van Schewick C, Körner G, Shalapour S, Rhein P, Karawajew L, Ludwig WD, Seeger K, Henze G, von Stackelberg A, Hagemeier C, Eckert C, Kirschner-Schwabe R.

J Clin Oncol. 2011 Aug 10;29(23):3185-93. doi: 10.1200/JCO.2011.34.8144. Epub 2011 Jul 11.

PMID:
21747090
42.

Mitochondrial genome variants in non-remitting ALL of childhood.

Back C, Knauss H, Ludwig WD, Schrappe M, Debatin KM, Beltinger C.

Br J Haematol. 2011 Dec;155(5):626-9. doi: 10.1111/j.1365-2141.2011.08743.x. Epub 2011 May 25. No abstract available.

PMID:
21615382
43.
44.

Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification.

Matutes E, Pickl WF, Van't Veer M, Morilla R, Swansbury J, Strobl H, Attarbaschi A, Hopfinger G, Ashley S, Bene MC, Porwit A, Orfao A, Lemez P, Schabath R, Ludwig WD.

Blood. 2011 Mar 17;117(11):3163-71. doi: 10.1182/blood-2010-10-314682. Epub 2011 Jan 12.

PMID:
21228332
45.

The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function.

Kox C, Zimmermann M, Stanulla M, Leible S, Schrappe M, Ludwig WD, Koehler R, Tolle G, Bandapalli OR, Breit S, Muckenthaler MU, Kulozik AE.

Leukemia. 2010 Dec;24(12):2005-13. doi: 10.1038/leu.2010.203. Epub 2010 Oct 14.

46.

[Open questions in the drug therapy of tumors with new active substances].

Ludwig WD, Schott G.

Onkologie. 2010;33 Suppl 7:6-10. doi: 10.1159/000320465. Epub 2010 Sep 16. German.

PMID:
20926907
47.

[The relation between publication bias and clinical trials funding].

Schott G, Pachl H, Ludwig WD.

Z Evid Fortbild Qual Gesundhwes. 2010;104(4):314-22. German.

PMID:
20701111
48.

Expression of cell-cell interacting genes distinguishes HLXB9/TEL from MLL-positive childhood acute myeloid leukemia.

Wildenhain S, Ruckert C, Röttgers S, Harbott J, Ludwig WD, Schuster FR, Beldjord K, Binder V, Slany R, Hauer J, Borkhardt A.

Leukemia. 2010 Sep;24(9):1657-60. doi: 10.1038/leu.2010.146. Epub 2010 Jul 1. No abstract available.

PMID:
20596032
49.

Childhood near-tetraploid acute lymphoblastic leukemia: an EGIL study on 36 cases.

Lemez P, Attarbaschi A, Béné MC, Bertrand Y, Castoldi G, Forestier E, Garand R, Haas OA, Kagialis-Girard S, Ludwig WD, Matutes E, Mejstríková E, Pages MP, Pickl W, Porwit A, Orfao A, Schabath R, Starý J, Strobl H, Talmant P, van't Veer MB, Zemanová Z; European Group for the Immunological Characterization of Leukemias (EGIL).

Eur J Haematol. 2010 Oct;85(4):300-8. doi: 10.1111/j.1600-0609.2010.01493.x.

PMID:
20561032
50.

[Hematopoietic growth factors. Possibilities and limitations].

Held TK, Hildebrandt MO, Ludwig WD.

Internist (Berl). 2010 Jul;51(7):863-71; quiz 872-3. doi: 10.1007/s00108-010-2641-2. German.

PMID:
20544173

Supplemental Content

Loading ...
Support Center